We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
- Authors
Tsoukas, Michael A.; Woo, Vincent; Tobe, Sheldon W.; Slee, April; Rapattoni, Wally; Ang, Fernando G.; Seufert, Jochen; Neuen, Brendon L.; Arnott, Clare; Mahaffey, Kenneth W.; Wheeler, David C.
- Abstract
In addition, generalizability of the results may be limited to individuals with previous CV events, high CV risk or nephropathy, similar to the patients enrolled in the CANVAS programme and CREDENCE trial. This post-hoc analysis assessed the effects of canagliflozin versus placebo on CV and kidney outcomes in patients with T2DM and high CV risk, and/or chronic kidney disease according to baseline treatment target achievement and risk factors. Keywords: canagliflozin; cardiovascular disease; diabetic nephropathy; type 2 diabetes EN canagliflozin cardiovascular disease diabetic nephropathy type 2 diabetes 2038 2042 5 06/06/23 20230701 NES 230701 BACKGROUND Management of type 2 diabetes mellitus (T2DM), a progressive metabolic disorder associated with substantial cardiovascular (CV) and kidney complications, includes risk factor optimization of glucose, blood pressure (BP) and lipids.
- Subjects
SODIUM-glucose cotransporters; TYPE 2 diabetes; CANAGLIFLOZIN; KIDNEYS
- Publication
Diabetes, Obesity & Metabolism, 2023, Vol 25, Issue 7, p2038
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.15057